Evidence map›Paper›PMID 39272971›Full record

ReviewCancers2024

Cellular and Microbial In Vitro Modelling of Gastrointestinal Cancer.

Kristina Žukauskaitė, Melissa Li, Angela Horvath, Sonata Jarmalaitė, Vanessa Stadlbauer

Abstract readReview
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Emerging advances in intestinal models for in vitro preclinical research.American journal of physiology. Gastrointestinal and liver physiology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kristina ŽukauskaitėDepartment of Gastroenterology and Hepatology, Medical University of Graz, 8036 Graz, Austria.
Melissa LiDepartment of Gastroenterology and Hepatology, Medical University of Graz, 8036 Graz, Austria.
Angela HorvathDepartment of Gastroenterology and Hepatology, Medical University of Graz, 8036 Graz, Austria.ORCID 0000-0001-7279-0628
Sonata JarmalaitėInstitute of Biosciences, Life Sciences Center, Vilnius University, 10257 Vilnius, Lithuania.ORCID 0000-0003-3719-0891
Vanessa StadlbauerDepartment of Gastroenterology and Hepatology, Medical University of Graz, 8036 Graz, Austria.ORCID 0000-0001-5508-8271

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human diseases are multifaceted, starting with alterations at the cellular level, damaging organs and their functions, and disturbing interactions and immune responses. In vitro systems offer clarity and standardisation, which are crucial for effectively modelling disease. These models aim not to replicate every disease aspect but to dissect specific ones with precision. Controlled environments allow researchers to isolate key variables, eliminate confounding factors and elucidate disease mechanisms more clearly. Technological progress has rapidly advanced model systems. Initially, 2D cell culture models explored fundamental cell interactions. The transition to 3D cell cultures and organoids enabled more life-like tissue architecture and enhanced intercellular interactions. Advanced bioreactor-based devices now recreate the physicochemical environments of specific organs, simulating features like perfusion and the gastrointestinal tract's mucus layer, enhancing physiological relevance. These systems have been simplified and adapted for high-throughput research, marking significant progress. This review focuses on in vitro systems for modelling gastrointestinal tract cancer and the side effects of cancer treatment. While cell cultures and in vivo models are invaluable, our main emphasis is on bioreactor-based in vitro modelling systems that include the gut microbiome.

Indexed as

bioreactor systemdisease modelgastrointestinal tractgut microbiomeintestinal modelin vitro model

Identifiers

PMID39272971
PMCPMC11394127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.